Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer – Pipeline Review, H1 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.
Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 29, 21, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 5 molecules, respectively.
Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc
Advenchen Laboratories LLC
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Biovista Inc
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Celgene Corp
Celldex Therapeutics Inc
Cytori Therapeutics Inc
Daiichi Sankyo Company Ltd
Ecrins Therapeutics SAS
Eisai Co Ltd
Ensol Biosciences Inc
F. Hoffmann-La Roche Ltd
Genelux Corp
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc
Hutchison MediPharma Ltd
Ignyta Inc
Immune Pharmaceuticals Inc
Immunomedics Inc
Johnson & Johnson
Loxo Oncology Inc
MacroGenics Inc
MaxiVAX SA
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Nerviano Medical Sciences Srl
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
Plexxikon Inc
Rodos BioTarget GmbH
Savoy Pharmaceuticals Inc
Synactix Pharmaceuticals Inc
Tarveda Therapeutics Inc
Vaccinex Inc
Vascular Biogenics Ltd
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Thyroid Cancer – Overview 9
Thyroid Cancer – Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 21
Thyroid Cancer – Therapeutics Assessment 22
Assessment by Target 22
Assessment by Mechanism of Action 26
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Thyroid Cancer – Companies Involved in Therapeutics Development 34
AbbVie Inc 34
Advenchen Laboratories LLC 34
AstraZeneca Plc 35
Bayer AG 35
BeiGene Ltd 36
Biovista Inc 36
Blueprint Medicines Corp 37
Boehringer Ingelheim GmbH 37
Celgene Corp 38
Celldex Therapeutics Inc 38
Cytori Therapeutics Inc 39
Daiichi Sankyo Company Ltd 39
Ecrins Therapeutics SAS 40
Eisai Co Ltd 40
Ensol Biosciences Inc 41
F. Hoffmann-La Roche Ltd 41
Genelux Corp 42
Genmab A/S 42
GlaxoSmithKline Plc 43
Gradalis Inc 43
Hutchison MediPharma Ltd 44
Ignyta Inc 44
Immune Pharmaceuticals Inc 45
Immunomedics Inc 45
Johnson & Johnson 46
Loxo Oncology Inc 46
MacroGenics Inc 47
MaxiVAX SA 47
Merck & Co Inc 48
Merck KGaA 48
Millennium Pharmaceuticals Inc 49
Nerviano Medical Sciences Srl 49
Novartis AG 50
Ono Pharmaceutical Co Ltd 51
Pfizer Inc 52
Plexxikon Inc 53
Rodos BioTarget GmbH 53
Savoy Pharmaceuticals Inc 54
Synactix Pharmaceuticals Inc 54
Tarveda Therapeutics Inc 55
Vaccinex Inc 55
Vascular Biogenics Ltd 56
Thyroid Cancer – Drug Profiles 57
AL-3818 – Drug Profile 57
BGB-283 – Drug Profile 60
BGBA-317 – Drug Profile 63
BLU-667 – Drug Profile 65
BVA-501 – Drug Profile 66
BVA-701 – Drug Profile 67
CDX-3379 – Drug Profile 68
ceritinib – Drug Profile 72
Charis-1000 – Drug Profile 79
CLM-24 – Drug Profile 80
CLM-29 – Drug Profile 81
CLM-3 – Drug Profile 82
CLM-94 – Drug Profile 83
crizotinib – Drug Profile 84
crolibulin – Drug Profile 91
dabrafenib mesylate – Drug Profile 93
dabrafenib mesylate + trametinib dimethyl sulfoxide – Drug Profile 98
docetaxel – Drug Profile 105
donafenib – Drug Profile 107
efatutazone – Drug Profile 108
enoblituzumab – Drug Profile 110
entrectinib – Drug Profile 113
ETD-5 – Drug Profile 120
everolimus – Drug Profile 121
FAZ-053 – Drug Profile 135
gemogenovatucel-T – Drug Profile 136
GI-6207 – Drug Profile 141
GLONC-2 – Drug Profile 143
GSK-2256098 – Drug Profile 144
HMPL-012 – Drug Profile 146
HuMax-AXL-ADC – Drug Profile 150
JB-002 – Drug Profile 151
larotrectinib – Drug Profile 152
lenvatinib mesylate – Drug Profile 157
LOXO-292 – Drug Profile 170
MGD-009 – Drug Profile 171
MVXONCO-1 – Drug Profile 173
nintedanib – Drug Profile 175
NMS-616 – Drug Profile 186
ofranergene obadenovec – Drug Profile 187
Oncoprev – Drug Profile 194
ONO-8430506 – Drug Profile 195
panobinostat – Drug Profile 196
pasireotide – Drug Profile 204
pazopanib hydrochloride – Drug Profile 208
PDR-001 – Drug Profile 217
pembrolizumab – Drug Profile 219
PEN-221 – Drug Profile 267
pexidartinib – Drug Profile 269
pimasertib hydrochloride + voxtalisib – Drug Profile 274
PLX-7486 – Drug Profile 276
PLX-8394 – Drug Profile 277
Recombinant Protein for Thyroid Cancer – Drug Profile 278
regorafenib – Drug Profile 279
rovalpituzumab tesirine – Drug Profile 291
RXDX-105 – Drug Profile 293
sacituzumab – Drug Profile 296
sapanisertib – Drug Profile 307
selumetinib sulfate – Drug Profile 310
Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer – Drug Profile 317
Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer – Drug Profile 318
Small Molecules to Inhibit ALK for Oncology – Drug Profile 319
Small Molecules to Inhibit PAK for Thyroid Cancer – Drug Profile 320
sunitinib malate – Drug Profile 321
SYN-001 – Drug Profile 326
temsirolimus – Drug Profile 327
TF-2 – Drug Profile 330
tipifarnib – Drug Profile 333
TQB-3234 – Drug Profile 337
trametinib dimethyl sulfoxide – Drug Profile 338
UB-941 – Drug Profile 343
utomilumab – Drug Profile 344
vemurafenib – Drug Profile 347
VIMO-001 – Drug Profile 355
VX-15 – Drug Profile 356
Thyroid Cancer – Dormant Projects 361
Thyroid Cancer – Discontinued Products 363
Thyroid Cancer – Product Development Milestones 364
Featured News & Press Releases 364
Appendix 377
Methodology 377
Coverage 377
Secondary Research 377
Primary Research 377
Expert Panel Validation 377
Contact Us 377
Disclaimer 378
List of Tables
Number of Products under Development for Thyroid Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Thyroid Cancer – Pipeline by AbbVie Inc, H1 2017
Thyroid Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017
Thyroid Cancer – Pipeline by AstraZeneca Plc, H1 2017
Thyroid Cancer – Pipeline by Bayer AG, H1 2017
Thyroid Cancer – Pipeline by BeiGene Ltd, H1 2017
Thyroid Cancer – Pipeline by Biovista Inc, H1 2017
Thyroid Cancer – Pipeline by Blueprint Medicines Corp, H1 2017
Thyroid Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017
Thyroid Cancer – Pipeline by Celgene Corp, H1 2017
Thyroid Cancer – Pipeline by Celldex Therapeutics Inc, H1 2017
Thyroid Cancer – Pipeline by Cytori Therapeutics Inc, H1 2017
Thyroid Cancer – Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Thyroid Cancer – Pipeline by Ecrins Therapeutics SAS, H1 2017
Thyroid Cancer – Pipeline by Eisai Co Ltd, H1 2017
Thyroid Cancer – Pipeline by Ensol Biosciences Inc, H1 2017
Thyroid Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Thyroid Cancer – Pipeline by Genelux Corp, H1 2017
Thyroid Cancer – Pipeline by Genmab A/S, H1 2017
Thyroid Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017
Thyroid Cancer – Pipeline by Gradalis Inc, H1 2017
Thyroid Cancer – Pipeline by Hutchison MediPharma Ltd, H1 2017
Thyroid Cancer – Pipeline by Ignyta Inc, H1 2017
Thyroid Cancer – Pipeline by Immune Pharmaceuticals Inc, H1 2017
Thyroid Cancer – Pipeline by Immunomedics Inc, H1 2017
Thyroid Cancer – Pipeline by Johnson & Johnson, H1 2017
Thyroid Cancer – Pipeline by Loxo Oncology Inc, H1 2017
Thyroid Cancer – Pipeline by MacroGenics Inc, H1 2017
Thyroid Cancer – Pipeline by MaxiVAX SA, H1 2017
Thyroid Cancer – Pipeline by Merck & Co Inc, H1 2017
Thyroid Cancer – Pipeline by Merck KGaA, H1 2017
Thyroid Cancer – Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Thyroid Cancer – Pipeline by Nerviano Medical Sciences Srl, H1 2017
Thyroid Cancer – Pipeline by Novartis AG, H1 2017
Thyroid Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Thyroid Cancer – Pipeline by Pfizer Inc, H1 2017
Thyroid Cancer – Pipeline by Plexxikon Inc, H1 2017
Thyroid Cancer – Pipeline by Rodos BioTarget GmbH, H1 2017
Thyroid Cancer – Pipeline by Savoy Pharmaceuticals Inc, H1 2017
Thyroid Cancer – Pipeline by Synactix Pharmaceuticals Inc, H1 2017
Thyroid Cancer – Pipeline by Tarveda Therapeutics Inc, H1 2017
Thyroid Cancer – Pipeline by Vaccinex Inc, H1 2017
Thyroid Cancer – Pipeline by Vascular Biogenics Ltd, H1 2017
Thyroid Cancer – Dormant Projects, H1 2017
Thyroid Cancer – Dormant Projects, H1 2017 (Contd..1), H1 2017
Thyroid Cancer – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Thyroid Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
